Research of quality indicators and stability of herbal species for mastopathy therapy
Keywords:mastopathy, medicinal plants, quality indicators, stability, microbiological purity
Topicality. Given the high incidence of breast pathologies and the limited pharmacological treatment, it is urgent to consider the possibility of using medicinal herbs in complex mastopathy therapy.
Aim. To study the quality indicators and stability during storage of the developed medicinal herbal species for complex mastopathy therapy.
Materials and methods. The study of the species samples named “Mastonorm” in different types of packaging was carried out using the methods of organoleptic, physicochemical, pharmacotechnological and biological research, which results in an objective assessment of the quality and stability of the developed species.
Results and discussion. In the course of the studies the weight loss in drying process was found , depending on the type of packaging from 9.7 to 10,86 %, total ash is in the range of 8.0-10.5 %, ash insoluble in hydrochloric acid, – in the range of 2.2-2.8 %, the weight loss in drying of the samples during the shelf life is in the range of 9.7-10.9 %. The content of extractive substances extracted with water from species, laid in four types of packaging, is 26.7-28.7 %. The amount of biologically active substances (flavonoids) in terms of the routine during the shelf life is 0.4-0.5 %. The results obtained meet the requirements for this dosage form and during storage remains almost unchanged. Tests for microbiological purity proved the compliance of the developed drug with the requirements of SPhU 2 ed., Item 2.6.12, 2.6.13.
Conclusions. The criteria for the specifications of the “Mastonorm” species under the sections “Description”, “Moisture content”, “Ash content”, “Ash insoluble in hydrochloric acid”, “Weight of packaging content”, “Quantitative content”, “Microbiological purity” are substantiated and investigated. The stability of the developed species for two years at the temperature 5 ± 3 °C and 25 ± 2 °C in different types of packaging was experimentally proved. Microbiological studies have established that the developed species “Mastonorm” in terms of microbiological purity meets the requirements of SPhU throughout the shelf life.
Tykhonovskyi, O. V. (2015). Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky, 3 (19), 81–86.
Vyshnevska, L. I., Zuikina, C. C. (2015). Zbirnyk naukovykh prats spivrobitnykiv NMAPO imeni P. L. Shupyka, 24 (5), 289–293.
Zuikina, S. S., Vishnevska, L. I. (2017). The pharmacotechnological studies of the phytospecies composition for the complex therapy of mastopathy. Vìsnik farmacìï, 2 (90), 43–47. https://doi.org/10.24959/nphj.17.2172
Zuikina, S., Vyshnevska, L. (2019). Research on the development of the composition and standardization of medicinal plants for complex mastopathy therapy. Management, economy and quality assurance in pharmacy, 4 (60), 22–28. https://doi.org/10.24959/uekj.19.33
Zuikina, S., Vyshnevska, L. (2018). Pat. № 117292 Ukraine. MPK51 A 61 K 36/11 (2006.01), A61K36/18 (2006.01). Fitozbir dlya likuvannya i profilaktyky
Gosudarstvennaia farmakopeia SSSR (11-th edition). (1987). Moscow: Meditcina, 1, 336; 2, 400.
Derzhavna farmakopeya Ukrayiny. (2015). Derzhavne pidpryyemstvo “Ukrayins’kyy naukovyy farmakopeynyy tsentr yakosti likars’kykh zasobiv”. Kharkiv: Derzhavne pidpryyemstvo “Ukrayins’kyy naukovyy farmakopeynyy tsentr yakosti likars’kykh zasobiv”, 1, 1128.
Glushchenko, A. V., Georgiiantc, V. A., Bevz, N. Yu. (2014). Nauchnye vedomosti BGU seriia “Meditcina. Farmatciia”, 11(182), 219–223.
Heorhiievskyi, V., Liapunov, M., Bezuhla, O., Piotrovska, A., Hryzodub, A. (2004). Nastanova 42-3.3:2004 Nastanovy z yakosti. Likarski zasoby. Vyprobuvannia stabilnosti. Kyiv: MOZ Ukrainy, 60.
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).